Ruptured Aneurysm SegmenttoWitnessHigher CAGRDuringForecast Period

According to the latest study on “Asia Pacific Brain Aneurysm Treatment Market Forecast to 2027 – COVID-19 Impact and Analysis –by Type, Condition, and End User,”the market was valued at US$ 576.71million in 2019 and is projectedto reach US$ 1,737.32millionby2027; it is expected to grow at a CAGR of 14.9%during 2020–2027. The report highlights trends prevailing in the Asia Pacific brain aneurysm treatmentmarket and the factors driving market along with those that act as hindrances.

Based on condition, the Asia Pacific brain aneurysm treatment market is segmented into unruptured aneurysm and ruptured aneurysm. In 2019, the unruptured aneurysm segment held a largershare of the market. However, the ruptured aneurysm segment is expected to grow at a fasterrate duringthe forecast period.

The growth of the Asia Pacific brain aneurysm treatmentmarket is attributed to the increasing incidences of neurological disorders such as stroke and brain aneurysms across Asia Pacific. However, the high cost of procedures limits the growth of market in this region.

Stryker Corporation, MicroPort Scientific Corporation, Terumo Corporation, Mizuho Medical Co,Ltd., and KANEKA CORPORATION are among the leading companies operating in the Asia Pacific brain aneurysm treatment market.

Asia Pacific Brain Aneurysm Treatment Market, By Region, 2019 (%)  

The report segments Asia Pacific brain aneurysm treatmentMarket as follows:

By Type

• Surgery
• Medication

By Condition

• Unruptured Aneurysm
• Ruptured Aneurysm

By End User

• Hospitals
• Clinics

By Country

• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific

Contact Us

Contact Person: Sameer Joshi 

Phone: +1-646-491-9876

Email Id: sales@businessmarketinsights.com